GlaxoSmithKline Receives FDA Approval for Cervarix Vaccine in Girls and Young Women

The FDA approved the Cervarix vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV). Genital HPV infections are the most common sexually-transmitted diseases in the United States. Cervarix, manufactured by GlaxoSmithKline, targets high-risk HPV types 16 and 18, the 2 strains responsible for about 70% of all cervical cancers. Cervarix is approved for use in girls and women aged 10 through 25. Cervarix protects against two strains of HPV that cause cervical cancer, while Gardasil protects against those two strains plus two other strains that cause genital warts.